TY - JOUR
T1 - Effects of yoga in men with prostate cancer on quality of life and immune response
T2 - a pilot randomized controlled trial
AU - Kaushik, Dharam
AU - Shah, Pankil K.
AU - Mukherjee, Neelam
AU - Ji, Niannian
AU - Dursun, Furkan
AU - Kumar, Addanki P.
AU - Thompson, Ian M.
AU - Mansour, Ahmed M.
AU - Jha, Richapriya
AU - Yang, Xiaoyu
AU - Wang, Hanzhang
AU - Darby, Nydia
AU - Ricardo Rivero, J.
AU - Svatek, Robert S.
AU - Liss, Michael A.
N1 - Funding Information:
The manuscript was copy-edited by Ms. Susan Albrecht at MedSurgBio Ltd. This work was supported by: (1) the ThriveWell Cancer Foundation (Dharam Kaushik); (2) P30 Cancer Center Support Grant from the National Cancer Institute (CA054174) (Mays Cancer Center at University of Texas Health San Antonio) (Dharam Kaushik) (3) the Roger L. And Laura D. Zeller Charitable Foundation Chair in Urologic Cancer (Robert S. Svatek), (4) the Glenda and Gary Woods Distinguished Chair in GU Oncology (Michael A. Liss), (5) Department of Defense, Prostate Cancer Research Program (PCRP) Physician Research Training Award. Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program under Award No. W81XWH-15-1-0441 (Michael A. Liss) (6) a Research Training Award (RP170345) from the Cancer Prevention & Research Institute of Texas (Furkan Dursun) (7) Stanley and Sandra Rosenberg Endowed Chair in Urologic Research (Dharam Kaushik) The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/9
Y1 - 2022/9
N2 - Background: Diagnosis and treatment of prostate cancer is associated with anxiety, fear, and depression in up to one-third of men. Yoga improves health-related quality of life (QoL) in patients with several types of cancer, but evidence of its efficacy in enhancing QoL is lacking in prostate cancer. Methods: In this randomized controlled study, 29 men newly diagnosed with localized prostate cancer were randomized to yoga for 6 weeks (n = 14) or standard-of-care (n = 15) before radical prostatectomy. The primary outcome was self-reported QoL, assessed by the Expanded Prostate Index Composite (EPIC), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT–F), Functional Assessment of Cancer Therapy-General (FACT-G) at baseline, preoperatively, and 6 weeks postoperatively. Secondary outcomes were changes in immune cell status and cytokine levels with yoga. Results: The greatest benefit of yoga on QoL was seen in EPIC-sexual (mean difference, 8.5 points), FACIT-F (6.3 points), FACT-Functional wellbeing (8.6 points), FACT-physical wellbeing (5.5 points), and FACT-Social wellbeing (14.6 points). The yoga group showed increased numbers of circulating CD4+ and CD8+ T-cells, more production of interferon-gamma by natural killer cells, and increased Fc receptor III expression in natural killer cells. The yoga group also showed decreased numbers of regulatory T-cells, myeloid-derived suppressor cells, indicating antitumor activity, and reduction in inflammatory cytokine levels (granulocyte colony-stimulating factor [0.55 (0.05–1.05), p = 0.03], monocyte chemoattractant protein [0.22 (0.01–0.43), p = 0.04], and FMS-like tyrosine kinase-3 ligand [0.91 (−0.01, 1.82), p = 0.053]. Conclusions: Perioperative yoga exercise improved QoL, promoted an immune response, and attenuated inflammation in men with prostate cancer. Yoga is feasible in this setting and has benefits that require further investigation. Trial registration: clinicaltrials.org (NCT02620033).
AB - Background: Diagnosis and treatment of prostate cancer is associated with anxiety, fear, and depression in up to one-third of men. Yoga improves health-related quality of life (QoL) in patients with several types of cancer, but evidence of its efficacy in enhancing QoL is lacking in prostate cancer. Methods: In this randomized controlled study, 29 men newly diagnosed with localized prostate cancer were randomized to yoga for 6 weeks (n = 14) or standard-of-care (n = 15) before radical prostatectomy. The primary outcome was self-reported QoL, assessed by the Expanded Prostate Index Composite (EPIC), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT–F), Functional Assessment of Cancer Therapy-General (FACT-G) at baseline, preoperatively, and 6 weeks postoperatively. Secondary outcomes were changes in immune cell status and cytokine levels with yoga. Results: The greatest benefit of yoga on QoL was seen in EPIC-sexual (mean difference, 8.5 points), FACIT-F (6.3 points), FACT-Functional wellbeing (8.6 points), FACT-physical wellbeing (5.5 points), and FACT-Social wellbeing (14.6 points). The yoga group showed increased numbers of circulating CD4+ and CD8+ T-cells, more production of interferon-gamma by natural killer cells, and increased Fc receptor III expression in natural killer cells. The yoga group also showed decreased numbers of regulatory T-cells, myeloid-derived suppressor cells, indicating antitumor activity, and reduction in inflammatory cytokine levels (granulocyte colony-stimulating factor [0.55 (0.05–1.05), p = 0.03], monocyte chemoattractant protein [0.22 (0.01–0.43), p = 0.04], and FMS-like tyrosine kinase-3 ligand [0.91 (−0.01, 1.82), p = 0.053]. Conclusions: Perioperative yoga exercise improved QoL, promoted an immune response, and attenuated inflammation in men with prostate cancer. Yoga is feasible in this setting and has benefits that require further investigation. Trial registration: clinicaltrials.org (NCT02620033).
UR - http://www.scopus.com/inward/record.url?scp=85119652335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119652335&partnerID=8YFLogxK
U2 - 10.1038/s41391-021-00470-w
DO - 10.1038/s41391-021-00470-w
M3 - Article
C2 - 34815548
AN - SCOPUS:85119652335
SN - 1365-7852
VL - 25
SP - 531
EP - 538
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 3
ER -